Literature DB >> 23226675

Fluorodeoxyglucose PET/CT and Tc99m-Sestamibi scan, dual tracer imaging in evaluation of osteonecrosis of jaw.

Prathamesh Joshi1, Mukta Kulkarni, Hrishikesh Joshi.   

Abstract

Entities:  

Year:  2012        PMID: 23226675      PMCID: PMC3510949          DOI: 10.4103/2230-8210.103051

Source DB:  PubMed          Journal:  Indian J Endocrinol Metab        ISSN: 2230-9500


× No keyword cloud information.
Sir, We read with great interest the case ‘Osteonecrosis of jaw associated with bisphosphonate use’ reported by Rastogi et al., in May-June 2012 issue.[1] We congratulate the authors for demonstrating the importance of keeping this diagnosis in mind while evaluating jaw pain. As the authors point out, Osteonecrosis of jaw (ONJ) is a much more common event in those patients receiving bisphosphonates for the treatment and prevention of cancer-related skeletal events (mainly intravenously), rather than in those patients receiving bisphosphonates (mainly orally) for nonmalignancy indications.[1] We would like to draw the readers’ attention to a nuclear medicine approach that can be useful to evaluate jaw pain and differentiate ONJ from neoplastic conditions affecting the jaw in patients known to have cancer. Histology is in some cases mandatory to differentiate ONJ from neoplastic osteolysis, but a biopsy can further contribute to bone damage. Hence the noninvasive imaging approach is worth describing. Nuclear medicine functional imaging obtained by a tracer that shows oncotropic properties, such as Tc99m-sestamibi, in comparison to a nontumor-specific tracer such as fluorodeoxyglucose (FDG), can support the differential diagnosis, thus avoiding invasive procedures in diagnosis of ONJ.[23] FDG is an exquisitely sensitive agent for tumor imaging with high negative predictive value; however, it is also known to be nonspecific and can sometimes show uptake in nonmalignant, infective/inflammatory pathology.[4] While Tc99m-sestamibi is considered to be a tumor-specific agent. The dual tracer approach is based on the criteria that malignant pathology causing jaw pain will be FDG as well as Tc99m-sestamibi avid. Alternatively, nonmalignant causes like ONJ, will be FDG avid but will be cold on Tc99m-sestamibi scan. This criteria has been primarily studied in differentiating ONJ from myeloma involving mandible.[25] Dual tracer imaging is an interesting approach to diagnose/exclude diagnosis of ONJ avoiding the risks of a surgical biopsy.
  4 in total

Review 1.  Clinical role of FDG PET in evaluation of cancer patients.

Authors:  Lale Kostakoglu; Harry Agress; Stanley J Goldsmith
Journal:  Radiographics       Date:  2003 Mar-Apr       Impact factor: 5.333

2.  Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis.

Authors:  Lucio Catalano; Silvana Del Vecchio; Fara Petruzziello; Rosa Fonti; Barbara Salvatore; Carmen Martorelli; Catello Califano; Giuseppe Caparrotti; Sabrina Segreto; Leonardo Pace; Bruno Rotoli
Journal:  Ann Hematol       Date:  2007-02-07       Impact factor: 3.673

Review 3.  Bisphosphonate-related osteonecrosis of the jaw: a pictorial review.

Authors:  Yoav Morag; Michal Morag-Hezroni; David A Jamadar; Brent B Ward; Jon A Jacobson; Samuel R Zwetchkenbaum; Joseph Helman
Journal:  Radiographics       Date:  2009-11       Impact factor: 5.333

4.  Osteonecrosis of jaw associated with bisphosphonate use.

Authors:  Ashu Rastogi; Vidya Rattan; Sanjay Kumar Bhadada
Journal:  Indian J Endocrinol Metab       Date:  2012-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.